Brief intro:
- Author: Wen-Hui Wu, Li-Zeng Zhu, Kang Liu, Lin Cao, Yuan-Ming Fan, Ping Zhou, Yue Zhang, Gaoxiang Ma, Jin-Feng Liu, Bao-Lin Liu, Lian-Wen Qi, Qun Liu
- Journal: Nature Communications
- Doi: https://www.doi.org/10.1038/s41467-025-68188-0
- Publication Date: 2026/1/9
Abstract
The concept of organ-organ communication in systemic diseases has gained significant traction. Despite accumulating evidence of liver-kidney crosstalk, the underlying regulatory mechanisms remain poorly understood. Here, we identify hepatokine fibrinogen-like protein 1 (FGL1) as a pivotal mediator driving liver-kidney communication in renal fibrosis. Integrative RNA sequencing and clinical analyses revealed FGL1 upregulation in the liver post-renal injury, with subsequent selective accumulation in fibrotic kidneys. Hepatocyte-specific knockout of FGL1 improved renal morphology, attenuated collagen deposition, and inhibited fibrosis markers in unilateral ureteral obstruction and adenine-induced mouse models. Conversely, FGL1 overexpression exacerbated renal fibrosis. Mechanistically, FGL1 binds to TGF-β receptor ALK5 and blocks its interaction with K48-linked polyubiquitin. Structural analyses identified critical residues in FGL1-ALK5 interaction. Hepatic FGL1 is transcriptionally regulated by STAT3, and activated by inflammatory cytokines (IL-6, IL-1β and TNF-α). Pharmacological inhibition by p-hydroxybenzaldehyde (screened out from 4080 compounds) or an anti-FGL1 monoclonal antibody significantly reduced renal fibrosis without hepatotoxicity. These findings establish FGL1 as a key mediator of pathogenic liver-kidney crosstalk and highlights therapeutic strategies to targeting organ-organ networks in renal fibrosis.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.